The effects of glucagon injection and infusion of glucose and volatile fatty acids were studied in onehumped camels. Twenty adult male camels were divided into four equal groups. The first group was infused with physiological saline and served as a control. The second group was injected with a single dose of glucagon, the third group was infused with glucose (50 %) in sterile saline, and the fourth group was infused with a volatile fatty acid (VFA) mixture. In the first, third and fourth groups, sampling was performed before the beginning of infusions (control time), and at 15, 30, 60 and 120 min post-infusion. Plasma glucagon concentrations were monitored in the second group at 5, 10, 15, 20, 30, 45, 90, 105 and 120 min after injection. For glucagon injection, glucose concentration peaked at 15 min post-injection, and tended to decrease thereafter. Plasma glucose concentrations showed significant rises above the basal value at all times after glucose infusion. VFA infusion had no apparent effect on plasma glucose concentration. After injection of glucagon, the plasma lactate concentration dropped significantly at 15 and 30 min, then increased gradually until it reached the original concentration of lactate at 120 min. However, glucose infusion elevated the plasma lactate concentration only at the end of the infusion period. A decrease in plasma lactate was observed at 60 min after VFA infusion. The present investigation provides evidence that the glucagon level in camels is higher than that in other ruminants and in man, and suggests that this is a probable species specificity, which would explain the higher level of glucose in the blood of camels than in that of other ruminants. The disappearance curve of injected glucagon had, as in other ruminants, an exponential two-compartment function. The hormone was rapidly distributed and was eliminated with a high rate of clearance.
Background: Carbapenem-resistant Enterobacteriaceae (CRE) have been disseminated worldwide and became a global threat. Due to limited therapeutic drugs plazomicin - a new semisynthetic aminoglycoside - have been suggested as an alternative option owing to its stability against aminoglycosides modifying enzymes (AMEs). This study aims to assess the in vitro activity of plazomicin against CRE isolates and to detect different types of carbapenemases among these isolates.
Material and Methods: In this study, 102 CRE isolates were collected from different clinical samples at Cairo University hospitals and the presence of carbapenemases was detected by modified carbapenem inhibition method (mCIM) and multiplex PCR tests. Plazomicin susceptibility testing was done using E test.
Results: The most frequently detected carbapenemase genes were blaNDM in 75 (73.5%) isolates, followed by blaOXA-48 in 57 (55.9%) and blaKPC in 16 (15.5%) isolates. Plazomicin was active against 32 (31.4%) isolates. Among the isolates carrying blaNDM gene only and those carrying blaOXA-48 gene only, 21% and 41% were sensitive to plazomicin, respectively. Plazomicin showed the highest sensitivity against CRE isolates compared to the other tested antibiotics.
Conclusion: Plazomicin might be a good option for treatment of infections caused by CRE. In health care settings where blaNDM gene is prevalent, plazomicin may not be a good therapeutic option for CRE infections.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.